Prostate Cancer International is
for 2011 by Great NonProfits
Today at the ASCO annual meeting, Maha Hussein presented the results a long-term, international, randomized trial of intermittent androgen deprivation (IAD) versus continuous androgen deprivation (CAD) in men with hormone-sensitive, metastatic prostate cancer.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: androgen deprivation, continuous, hormone therapy, intermittent, outcome, survival | 1 Comment »
The key prostate cancer presentations today at the annual meeting of the American Society of Clinical Oncology (ASCO) were all given at a morning session on high-risk and advanced prostate cancer.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, enzalutamide, MDV3100 | 2 Comments »
Studies to be presented at the ASCO meeting next week suggest that: (a) high-dose ketoconazole has very limited activity in the treatment of men who have already been treated with abiraterone acetate; (b) men treated with either high-dose ketoconazole or abiraterone acetate (or both) can still respond to docetaxel-based chemotherapy.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, castration-resistant, chemotherapy, CRPC, ketoconazole, outcome, sequence | 1 Comment »
A poster to be presented at the upcoming ASCO annual meeting gives us some insights into the actual behaviors of physicians and their patients regarding the use of active surveillance today in the “real world” of clinical practice (as opposed to clinical trials and case series at academic medical centers).
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment, Uncategorized | Tagged: active surveillance, low risk, Management | 4 Comments »
How did we all miss this? This may be the single most important paper presented at the annual meeting of the American Urological Association this year!
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: air, misinformation, risk, spread | 5 Comments »
An article in The Washington Post today discusses an initiative through which a group of about 40 specialists in the management of advanced forms of genitourinary cancers (including prostate cancer) get together to share ideas and knowledge to help their patients.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: advanced, GUMDROP, referral, trials | Leave a Comment »
Acccording to an article on the Medscape web site today, the convicted “Lockerbie bomber,” Abdelbaset al Megrahi, finally died on Sunday, 2 years and 9 months after his release from a Scottish prison on compassionate grounds because he was close to dying of terminal prostate cancer.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, al Megrahi, survival | 9 Comments »
There is a “nice” post today about surviving chemotherapy on Dr. Craig Hildreth’s cancer blog on the CancerNetwork.com web site. (“Nice” is in inverted commas because not much about chemotherapy is actually nice … but if you, your oncologist, and the oncologist’s office team think about chemo in the way Dr. Hildreth describes, it sure [...]
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: chemotherapy | Leave a Comment »
A media release issued by Henry Ford Health System earlier today has a distinctly misleading headline that reads as follows: “Higher hospital volume more important than surgeon experience in outcome of prostate cancer surgery.” You need to read the content of the media release with care to understand that this headline is by no means [...]
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: hospital, outcome, surgery, surgical, volume | 2 Comments »
According to information on the web site of the National Institute for Clinical Excellence (NICE), revised draft guidance has been issued by NICE regarding the routine use of abiraterone acetate.
Filed under: Drugs in development, Management, Treatment | Tagged: abiraterone, access, NICE, UK | 1 Comment »
According to the abstract of a paper to be presented at the upcoming meeting of the American Society for Clinical Oncology in Chicago at the beginning of June, 24 weeks of treatment with neoadjuvant abiraterone acetate + prednisone + an LHRH agonist appears to be able to eliminate visible risk of prostate cancer in post-surgical [...]
Filed under: Diagnosis, Drugs in development, Management, Risk, Treatment, Uncategorized | Tagged: abiraterone, dutasteride, enzalutamide, leuprolide, MDV3100, neoadjuvant, pre-surgical | 6 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site